Chronic pruritus is difficult to treat. Current treatment options are frequently ineffective and new therapeutic approaches are urgently needed. Avenanthramides are active substances in oats that exhibit anti-inflammatory effects. Their potential to interrupt pruritus mechanisms was investigated in this study. It was found that the synthetic analog dihydroavenanthramide D (DHAvD) can interact with the neurokinin-1 receptor (NK1R) and inhibit mast cell degranulation. DHAvD also affects inflammatory processes and reduces secretion of the cytokine interleukin-6. Our findings indicate that DHAvD may act as a NK1R inhibitor and could be a promising candidate for topical treatments of chronic pruritus.
| BACKGROUND
The pathogenesis of chronic pruritus (CP) is complex and associated with a variety of diseases. [1] CP may often remain refractory, although actual therapeutic approaches may reduce symptoms. [2] Persistent symptoms and the current lack of available treatment options greatly affect patients' quality of life (S1). Hence, there is an urgent need for the development of new therapies taking both the identification of new targets and their appropriate therapeutic agents into consideration.
Avenanthramides (AVN), a group of amide esters comprising various anthranilic and cinnamic acid partial structures, are active substances found in oats. [3] AVN have been found to exhibit various anti-inflammatory and antipruritic effects [4, 5] (S2) following topical administration. Their underlying mechanisms and targeted molecules remain unexplained.
| QUESTIONS ADDRESSED
In this study, we investigated new potential targets for synthetic AVN dihydroavenanthramide D (DHAvD), as well as its cutaneous, antiinflammatory effects.
| EXPERIMENTAL DESIGN
To investigate the underlying targets of DHAvD's properties (0. 
| MC degranulation
The effects of DHAvD on substance P (SP)-induced MC degranulation in the human MC line LAD2 were assessed by quantifying the enzymatic activity of beta-hexosaminidase in the supernatant.
| Intracellular calcium release
Intracellular calcium (Ca 2+ ) release was measured in the KNRK-PAR2, HEK-NK1R and respective wild-type cell lines. Its release was induced by PAR2-and NK1R-specific agonists and antagonists (see methods in Appendix S1) that were used to inhibit receptormediated signals.
| Inflammatory response in skin cells
Normal human epidermal keratinocytes (Promocell, Heidelberg, Germany) were stimulated for 3 hours with polyinosinic: polycytidylic acid (poly I:C; 20 μg/mL) and DHAvD. For another experiment, the monocytic cell line U937 was differentiated with 10 ng/mL PMA into macrophage-like cells for 48 hours (S3-S5). The differentiated cells were pre-incubated with DHAvD or vehicle for 1 hour and then stimulated with lipopolysaccharide (LPS) for a further 2 hours. Supernatants and cells were collected, and the cytokine production was quantified by qPCR and ELISA.
More detailed information on the materials and methods can be found in the Supporting information.
| Statistics
Data are shown as mean ± SEM. All reported P values were calculated 
| SP-induced MC degranulation is diminished by DHAvD
Peripheral tissue MC produce and release pro-inflammatory mediators (S6-S7) following activation, leading to inflammation or pruritus.
Following receptor activation, degranulation begins with the release of Ca 2+ from the endoplasmic reticulum into the cytosol (S8). MC express functional receptors for the NK1R agonist SP and NK2R agonist neurokinin-A (NKA) [6] (Figs S1A, S2A). Only SP was found to activate LAD2. MC degranulation was found to be reduced by both the NK1R antagonist L732,138 and DHAvD. The latter showed an even greater inhibitory effect ( Figure 1A ).
| DHAvD inhibited SP-mediated Ca 2+ release
Activation of certain receptors (i.e. NK1R and PAR2) can induce a phos-
signalling pathway, resulting in inflammation due to the production of pro-inflammatory cytokines such as interleukin (IL)-6 (S9). Both receptors are involved in the induction and maintenance of pruritus [7] (S10-S13).
We observed the effect of DHAvD on Ca 2+ release using HEK-NK1R
and KNKR-PAR2 cells. An analysis of the cells expressing PAR2 revealed that DHAvD produced no effects (data not shown). Interestingly, SP and NKA were able to markedly increase Ca 2+ release in HEK-NK1R, but not in HEK293 cells ( ( Figure 1D ). In contrast, the NK2R antagonist MEN10376 failed to reduce the NKA-induced release ( Figure 1E ). With a lower affinity, NKA can bind to the NK1R (S14). Therefore, the observed NKA-induced Ca 2+ release may be due to a binding of NKA to the NK1R. L732,138 was thus able to inhibit the NKA-stimulated signal ( Figure 1F ). 
| Anti-inflammatory effects of DHAvD
It is already known that in some pruritic diseases, an increased serum level of IL-6 may correlate with the severity of pruritus (S15, S16).
We used two TLR agonists, poly I:C (S17-S18) and LPS (S17, S19), to induce IL-6 secretion in keratinocytes and macrophages. Both are known to induce cytokine secretion via the NK1R pathway (S20, S21, for more information see conclusion in Appendix S1). As depicted in
Figures 2A and C, DHAvD was able to significantly reduce IL-6 secretion levels as well as its expression in these cells (Figure 2B, D) .
| CONCLUSION
Dihydroavenanthramide D interacts with the NK1R and has exhibited anti-inflammatory effects by blocking IL-6 expression in keratinocytes and macrophages, as well as MC degranulation. These mechanisms play an important role in the induction of pruritus. [8] MC release histamine and other pruritogenic mediators that are either directly or indirectly involved in pruritus induction in a variety of itchy diseases, such as prurigo nodularis. SP/NK1R signalling (for more information, see conclusion in Appendix S1) is thus most likely influenced by DHAvD. Interestingly, the NK1R has also recently been identified as an important target for treatments for pruritus . [9] Our results suggest that DHAvD is linked to SP-induced cell responses via the NK1R and represent a promising candidate for future topical treatments for pruritic diseases.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.
Appendix S1 Supplementary Methods and Materials
Data S1 Supplementary References accumulation has received considerable interest in the field of cosmetics. [1, 2] Peptides are potentially useful as active ingredients for cosmetics because of their bioactivity relevant to skin care and biosafety. [3, 4] A method called "positional scanning synthetic peptide combinatorial library" is useful for the screening of various bioactive peptides. [5, 6] 
| QUESTIONS ADDRESSED
The aim of this study was to identify antimelanogenic peptides by " positional scanning of a synthetic peptide combinatorial library."
| EXPERIMENTAL DESIGN
The synthetic hexapeptide combinatorial library consisted of six po- 
| RESULTS
Preliminary positional scanning ( (Fig. S3) .
The binding of α-MSH to melanocortin 1 receptors activates cyclic AMP-dependent signalling pathways that trigger the expression of melanogenic enzymes such as tyrosinase (TYR), TYR-related protein 1 (TYRP1), and dopachrome tautomerase (DCT). [7] [8] [9] As shown in forskolin, an adenylate cyclase activator (Fig. S4 ).
